… to inhibit the tyrosine kinase of ABL and BCR-ABL with high selectivity 13 ; only the tyrosine
kinases … = 0.25 μmol/L for BCR-ABL autophosphorylation). The data indicated activity against …

… that selectively inhibit the aberrant BCR-ABL tyrosine kinase. … ), is the first BCR-ABL tyrosine
kinase inhibitor (TKI) to be … the ABL kinase domain or overexpression of BCR-ABL could …

Introduction: Breakpoint cluster region Abelson (Bcr-Abl) tyrosine kinase (TK) is a constitutively
activated cytoplasmic TK and is the underlying cause of chronic myeloid leukemia (CML). …

… Based on this, we developed an assay for Bcr-Abl kinase inhibition, by examining the
relative proportion of Crkl isoforms before and during treatment. These assays showed that a …

… a kinase inhibitor with a broader specificity that may target additional kinases upstream or
downstream of Bcr-Abl, thereby decreasing the overall oncogenic potency of the Bcr-Abl effect …

… The two reports by Druker and colleagues in this issue of the Journal, 5,6 which document
the clinical efficacy of the BCR-ABL tyrosine kinase inhibitor STI571 in CML, must be …

… tyrosine kinase activity of the protein is required for its oncogenic activity. For these reasons,
an inhibitor of the BCR-ABL tyrosine kinase … screening for tyrosine kinase inhibitors and its …

… Bcr-Abl tyrosine kinase as an ideal target for validating the clinical utility of protein kinase
inhibitors… Through these efforts, we believe that the Bcr-Abl kinase inhibitor story will be but the …

… inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the
BcrAbl fusion protein… is that with the tyrosine kinase inhibitor, Bcr-Abl protein is still present, but …

… In this respect, the remarkable clinical success of the ABL tyrosine kinase inhibitor (TKI) 4,5
imatinib mesylate (formerly STI571 or CGP 5148B; Gleevec, Novartis) in the treatment of …